February 12, 2014 /

ACT DMD Update with PTC (February 2014)

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

ACT DMD Update with PTC (February 2014)

On February 5, 2014, Dr. Robert Spiegel, Chief Medical Officer at PTC Therapeutics, presented an update about PTC’s Phase 3 study of ataluren, now known as the Ataluren Confirmatory Trial in DMD (ACT DMD).
Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

This field is for validation purposes and should be left unchanged.
BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo